BioTuesdays

Tag - H.C. Wainwright

Shattuck Labs
Markets

HCW starts Shattuck Labs at buy; PT $28

H.C. Wainwright initiated coverage of Shattuck Labs (NASDAQ:STTK) with a “buy” rating and price target of $28. The stock closed at $3.84 on April 29. To overcome the shortcomings of current immunomodulatory cancer...

May 2, 2022
Vera-Therapeutics
Markets

HCW starts Vera Therapeutics at buy; PT $35

H.C. Wainwright launched coverage of Vera Therapeutics (NASDAQ:VERA) with a “buy” rating and $35 price target. The stock closed at $20 on April 29. Vera is a clinical-stage biotech company focused on developing disease...

May 2, 2022
Syndax Pharma Logo
Markets

HCW starts Syndax Pharma at buy; PT $31

H.C. Wainwright initiated coverage of Syndax Pharmaceuticals (NASDAQ:SNDX) with a “buy” rating and $31 price target. The stock closed at $17.51 on April 8. Syndax is a clinical-stage biopharmaceutical company focused on...

April 11, 2022
Bioatla
Markets

HCW starts BioAtla at buy; PT $25

H.C. Wainwright launched coverage of BioAtla (NASDAQ:BCAB) with a “buy” rating and $25 price target. The stock closed at $5.77 on March 18. BioAtla is a clinical-stage biopharmaceutical company developing novel...

March 21, 2022
Esperion Therapeutics Logo
Markets

HCW starts Esperion at buy; PT $22

H.C. Wainwright initiated coverage of Esperion Therapeutics (NASDAQ:ESPR) with a “buy” rating and price target of $22. The stock closed at $4.57 on March 9. Esperion is a commercial-stage company focused on development...

March 10, 2022
Celyad Logo
Markets

HCW cuts Celyad Oncology to neutral; removes PT

H.C. Wainwright downgraded Celyad Oncology (NASDAQ:CYAD) to “neutral” from “buy” and removed its price target after the company paused dosing and enrollment in its Phase 1b KEYNOTE-B79 study. Shares of Celyad were...

February 28, 2022
Inozyme Pharma
Markets

HCW starts Inozyme at buy; PT $33

H.C. Wainwright initiated coverage of Inozyme (NASDAQ:INZY) with a “buy” rating and $33 price target. The stock closed at $6.10 on Feb. 4. Inozyme is a rare disease biopharmaceutical company focused on developing...

February 7, 2022